Your session is about to expire
← Back to Search
Lutathera + Azedra for Gastrointestinal Cancer (SPORE-3 Trial)
SPORE-3 Trial Summary
This trial is testing the best tolerated doses of two different radioactive drugs, Lutathera and Azedra, when given together to treat neuroendocrine tumors in the middle part of the gut.
SPORE-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSPORE-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SPORE-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has been confirmed by lab tests.My disease is at least 1.5 cm big as shown on a scan.My tumor is a low or intermediate grade neuroendocrine tumor, likely started in the midgut.I am mostly active and can care for myself.I haven't had cancer treatment in the last 4 weeks and any side effects are mild.I have had radiation therapy that affected less than 25% of my bone marrow.Your healthcare professionals believe that you are at a higher risk of falling.I have been diagnosed with pheochromocytoma.My doctor has recommended LUTATHERA® or AZEDRA® for my treatment.I do not have another cancer that would interfere with this study's treatment.I can stop taking medications that affect MIBG uptake, or have approval to continue.I have had heart failure with a low heart pumping rate.I haven't taken any experimental drugs in the last 4 weeks.I am currently pregnant.I have received radiation of more than 16 Gy to my kidneys.I am between 18 and 80 years old.I have been diagnosed with paraganglioma.You have had allergic reactions to similar substances as Octreoscan® or Netspot™.If you are currently breastfeeding, you cannot participate in the study.I have undergone peptide-receptor radiotherapy.
- Group 1: Combination Therapy
- Group 2: Lutathera® only
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities to become involved in this clinical trial?
"This clinical trial is currently not accepting patient applications. It was initially posted on the 12th of December in 2023 and most recently updated on the 7th of July 2022. However, for those still seeking a medically-related study, 2483 trials are actively recruiting patients with neuroendocrine tumors and 27 studies require volunteers for Azedra research."
What has been the primary objective of Azedra's application?
"Azedra is the most common treatment for paraganglioma, as well as neoplasm metastasis, primary neuroblastomas and irresectable, iobenguane-scan positive pheochromocytomas."
Who is the ideal demographic for involvement in this clinical study?
"This medical trial has strict eligibility criteria, seeking patients aged between 18 and 80 who have been diagnosed with neuroendocrine tumors. Roughly 50 individuals are being recruited for the study."
How many individuals are taking part in this experiment?
"This study is currently not enrolling patients, having been initially posted on December 1st 2023 and last updated July 7th 2022. Alternatives are available with 2483 medical trials that accept participants suffering from neuroendocrine tumours and 27 studies for Azedra still recruiting."
Is this investigation open to individuals over the age of 45?
"This clinical trial is seeking subjects with an age bracket of 18 to 80 years old."
Share this study with friends
Copy Link
Messenger